following an abbreviated submission:
follitropin delta (Rekovelle®) is accepted for restricted use within NHSScotland.
Indication under review: controlled ovarian stimulation for the development of multiple follicles in women undergoing assisted reproductive technologies (ART) such as an in vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) cycle.
SMC restriction: for use in normal responders (patients with an anti-Müllerian hormone level of >5.4 pmol/L) or high responders (patients with an anti-Müllerian hormone level of ≥25 pmol/L).
Follitropin delta offers an additional treatment choice in the therapeutic class of gonadotropins.
This advice applies only in the context of approved NHSScotland Patient Access Scheme (PAS) arrangements delivering the cost-effectiveness results upon which the decision was based, or PAS/ list prices that are equivalent or lower.
Download detailed advice277KB (PDF)
Medicine details
- Medicine name:
- follitropin delta (Rekovelle)
- SMC ID:
- SMC2670
- Indication:
Controlled ovarian stimulation for the development of multiple follicles in women undergoing assisted reproductive technologies (ART) such as an in vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) cycle.
- Pharmaceutical company
- Ferring Pharmaceuticals Ltd
- BNF chapter
- Obstetrics, gynaecology, and urinary-tract disorders
- Submission type
- Abbreviated
- Status
- Restricted
- Date advice published
- 08 July 2024